Recent News

• 06.02.2025 - Lyra Therapeutics Reports Positive Results from the ENLIGHTEN 2 Phase 3 Trial of LYR-210 Achieving Statistically Significant Results for Primary and Key Secondary Endpoints in the Treatment of Chronic Rhinosinusitis (CRS)
• 06.02.2025 - Lyra Therapeutics Reports Positive Results from the ENLIGHTEN 2 Phase 3 Trial of LYR-210 Achieving Statistically Significant Results for Primary and Key Secondary Endpoints in the Treatment of Chronic Rhinosinusitis (CRS)
• 05.07.2025 - Lyra Therapeutics to Present 52-week Extension Stage Results for ENLIGHTEN 1 Phase 3 Study for LYR-210 for the Treatment of Chronic Rhinosinusitis at COSM 2025
• 05.07.2025 - Lyra Therapeutics to Present 52-week Extension Stage Results for ENLIGHTEN 1 Phase 3 Study for LYR-210 for the Treatment of Chronic Rhinosinusitis at COSM 2025
• 05.06.2025 - Lyra Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate Update
• 05.06.2025 - Lyra Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate Update

Recent Filings

• 05.19.2025 - 8-K Current report
• 05.16.2025 - 4 Statement of changes in beneficial ownership of securities
• 05.16.2025 - 4 Statement of changes in beneficial ownership of securities
• 05.16.2025 - 4 Statement of changes in beneficial ownership of securities
• 05.16.2025 - 4 Statement of changes in beneficial ownership of securities
• 05.09.2025 - DEFA14A Additional definitive proxy soliciting materials and Rule 14(a)(12) material
• 05.06.2025 - EX-99.1 EX-99.1
• 05.06.2025 - 10-Q Quarterly report [Sections 13 or 15(d)]
• 05.06.2025 - 8-K Current report
• 04.25.2025 - 144 Report of proposed sale of securities